Brian Lian: Yes. Great question, Yale. We will be using the pen type device. And we would hope that’s available prior to initiation of the next clinical study, but we’re not going to let that be a gating factor. So if the device is not ready, we would plan to start the study with vial and syringe and then transition on to the auto-injector.
Yale Jen: But do you anticipate at one point, even whether you start earlier before that or later that you need a bridging study for that? Or you think that PK data could be supportive?
Brian Lian: Well, no, I don’t think we would need a bridging study at this point. That’s not what we’re contemplating. I mean, if we have to do when we would. But I don’t think that’s going to be a requirement we would transition people.
Yale Jen: Okay, great. Thanks and congrats on the progress further.
Brian Lian: Thanks a lot, Yale.
Operator: The next question comes from Justin Zelin with BTIG. Please go ahead.
Justin Zelin: Thanks for taking the questions and congrats on the progress. Brian, you just mentioned for the VOYAGE study for fibrosis, you mentioned that there might be a few patients here. Can you just remind us if the study is powered to show a difference in fibrosis in the study? And I have a follow-up.
Brian Lian: Yes. Thanks, Justin. It wasn’t powered on Fibrosis. It was powered on NASH resolution rates. And I’m not sure we ever disclosed the power. It’s in the 80% range to show approximately a 20% delta on NASH resolution. But it was not designed around fibrosis since that generally requires quite a bit larger end than we have in this study.
Justin Zelin: Understood. That’s helpful. And maybe I’ll ask because I don’t think any others have asked yet. Just expectations on 0214 for X-ALD, what would be a success here in your view for the Phase 1b.
Brian Lian: Yes. Yes. So we have previously shown with that compound, somewhere in the 20% range on LDL reduction and in the 20% range for ApoB and [Indiscernible]. So we know it’s effective at lipid reduction. And we also looked at very long chain fatty acids in the healthy volunteers. It’s kind of tough to look because they’re healthy volunteers, and they don’t really have abnormalities and very long chain fatty acids, but we did see some reductions in very long-chain fatty acids in the prior Phase 1 experience. So if we can see somewhere in the mid- to high teens on the very long chain fatty acid reduction, that would be pretty interesting, hopefully, more than that, but that would be probably the gating factor to consider further development in X-linked adrenoleukodystrophy.
Justin Zelin: Excellent. Thanks for taking my questions.
Brian Lian: Thanks, Justin.
Operator: This concludes our question-and-answer session. I would like to turn the conference back over to Stephanie Diaz for any closing remarks.
Stephanie Diaz: Thank you again for your participation and continued support of Viking Therapeutics. We look forward to updating you again in the coming months. Have a good afternoon.
Operator: The conference has now concluded. Thank you for attending today’s presentation. You may now disconnect.
